



European Union
European Regional
Development Fund



Investing
in your future



38TH ANNUAL MEETING OF THE
EUROPEAN SOCIETY FOR PAEDIATRIC INFECTIOUS DISEASES

VIRTUAL MEETING
26-29
OCTOBER
2020

Assessment of glomerular filtration rate by population pharmacokinetics of iohexol in children and young adults with cancer and infection

Hiie Soeorg¹, Aveli Noortoots², Jana Lass³, Kadri Saks⁴, Maarja Karu⁴, Irja Lutsar¹, Lenne-Triin Kõrgvee⁵

¹University of Tartu, Department of Microbiology, Tartu, Estonia, ²University of Tartu, Institute of Clinical Medicine, Tartu, Estonia,

³Tartu University Hospital, Pharmacy, Tartu, Estonia, ⁴Tallinn Children's Hospital, Department of Haematology and Oncology, Tallinn, Estonia,

⁵Tartu University Hospital, Hematology-Oncology Clinic, Tartu, Estonia



Conflict of Interest



X	No, Nothing to disclose
	Yes, please specify

Company / Name	Honoraria / Expense	Consulting / Advisory Board	Funded Research	Royalties / Patent	Stock Options	Ownership / Equity Position	Employee	Other (Please specify)



Background

Children with cancer and infection may develop **augmented renal clearance**



Sub-therapeutic concentrations of antibiotics



Therapeutic failure

Adjustment in dosing



Correct assessment of renal function

- ▶ Most widely used creatinine-based eGFR equations imprecise
- ▶ Cystatin C-based eGFR could perform better
- ▶ Exogenous (e.g. iohexol) markers are preferred



Aim



- ▶ We aimed to
 - ▶ describe renal function by measured GFR using **iohexol clearance** and
 - ▶ assess the predictive performance of **creatinine- and cystatin C-based eGFR** equations
- in children and young adults with cancer and infection.



Methods

Hospitalised patients aged **0.5-25 years**

- with suspected/confirmed **infection** receiving piperacillin-tazobactam or cefepime
- **eGFR ≥ 70 mL/min/1.73 m²** according to Schwartz (children, <19 years) or MDRD or CKD-EPI equation (adults, ≥ 19 years)

Iohexol administered within 24 h up to 6 d after start of treatment with antibiotics

Iohexol concentrations measured prior to, 5 min, 0.5, 3-3.5, 5.5-8 h after administration

Iohexol concentration data described by **population pharmacokinetic model** in NONMEM

GFR=clearance (L/h)/60*1000/(body surface area (m²)) x 1.73

Creatinine and **cystatin C** measured 3 h later

eGFR calculated by 21 most common equations

GFR and eGFR compared in terms of **bias** and **accuracy**



Children and young adults



	Children (<19 years) (n=23)	Adults (≥19 years) (n=9)
Age (years) – median (range)	10 (0.7...17)	23 (20...25)
Male – n (%)	11 (47.8)	6 (66.7)
Body mass index z-score -2 to 2 – n (%)	18 (78%)	
Body mass index (kg/m ²) – median (range)		24.9 (17.9-33.3)
eGFR (mL/min/1.73 m ²)* – median (range)	148 (74 ...234)	135 (105...177)

*eGFR value of 914 mL/min/1.73 m² in one child excluded as outlier.



Iohexol population pharmacokinetic model

- ▶ Three-compartment model:

$$CL = 6.50 \times (\text{weight}/70)^{0.75} \times e^n,$$

$$V = 6.53 \times (\text{weight}/70),$$


$$Q_{p1} = 13.5,$$

$$V_{p1} = 8.33 \times (\text{weight}/70),$$

$$Q_{p2} = 0.72,$$

$$V_{p2} = 10.2$$

- ▶ Median (range) GFR was **98 (68-138) mL/min/1.73 m²** in children (<19 years) and **112 (70-140) mL/min/1.73 m²** in adults (≥19 years).




eGFR vs GFR

► All eGFR equations **overestimated** GFR and were **inaccurate**.

Equation	Bias (mL/min/1.73 m ²)	P10 (%)
Schwartz	-27	26
CKD-EPI	-21	22
MDRD	-26	33
Lund Malmö revised	-3	48
Gao	-6	45
Schwartz _{CysC}	-4	23

Bias = median GFR-eGFR

P10 = percentage of eGFR within ±10% of GFR



Conclusions

- ▶ In children and young adults with cancer and infection creatinine- and cystatin C-based eGFR equations
 - ▶ overestimate GFR and
 - ▶ are with poor precision and accuracy.

- ▶ Adjustment of doses of renally eliminated antibiotics may need more reliable renal function measurements than creatinine- and cystatin C-based eGFR equations.





Acknowledgments

- ▶ This study was funded by Estonian Research Council (PUT718, PUT1197, IUT34-24) and European Union through European Regional Development Fund.

